AEVI-007

Avalo Therapeutics, Inc. · Phase 1 active Small molecule

At a glance

Generic name	AEVI-007
Sponsor	Avalo Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis (PHASE2)
Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma (PHASE1)
A Study to Evaluate Camoteskimab in Participants With Still's Disease (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AEVI-007 CI brief — competitive landscape report
AEVI-007 updates RSS · CI watch RSS
Avalo Therapeutics, Inc. portfolio CI